New antibody therapy targets Hard-to-Treat cancers in early trial

NCT ID NCT06005493

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called AZD5863 in adults with advanced stomach, gastro-esophageal junction, pancreatic, or esophageal cancers that have spread. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to attack them. The main goals are to check safety and find the right dose, while also seeing if it shrinks tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Research Site

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Research Site

    WITHDRAWN

    New York, New York, 10065, United States

  • Research Site

    RECRUITING

    Beijing, 100142, China

  • Research Site

    RECRUITING

    Beijing, 101199, China

  • Research Site

    RECRUITING

    Shandong, China

  • Research Site

    RECRUITING

    Toulouse, 31059, France

  • Research Site

    RECRUITING

    Villejuif, 94805, France

  • Research Site

    RECRUITING

    Chūōku, 104-0045, Japan

  • Research Site

    RECRUITING

    Kashiwa, 227-8577, Japan

  • Research Site

    RECRUITING

    Kōtoku, 135-8550, Japan

  • Research Site

    RECRUITING

    Amsterdam, 1081 HV, Netherlands

  • Research Site

    RECRUITING

    Groningen, 9713 GZ, Netherlands

  • Research Site

    RECRUITING

    Rotterdam, 3015 GD, Netherlands

  • Research Site

    RECRUITING

    Seoul, 03080, South Korea

  • Research Site

    RECRUITING

    Seoul, 03722, South Korea

  • Research Site

    RECRUITING

    Seoul, 05505, South Korea

  • Research Site

    RECRUITING

    Seoul, 06351, South Korea

  • Research Site

    RECRUITING

    Kaohsiung City, 80756, Taiwan

  • Research Site

    RECRUITING

    Tainan, 70403, Taiwan

  • Research Site

    RECRUITING

    Taoyuan, 00333, Taiwan

  • Research Site

    RECRUITING

    Dundee, DD1 9SY, United Kingdom

  • Research Site

    RECRUITING

    London, E1 1BB, United Kingdom

  • Research Site

    RECRUITING

    Metropolitan Borough of Wirral, CH63 4JY, United Kingdom

  • Research Site

    RECRUITING

    Oxford, OX3 7LE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.